Thomas Carpenter Yale University School of Medicine New Haven, Connecticut, USA

Similar documents
X-Linked Hypophosphatemia (XLH) Case Study: A Dynamic Development Model for Rare Disease

Results Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy

X-linked hypophosphatemic rickets across the lifespan

Conventional therapy n=32. RGI-C Score (Primary Endpoint) LS Mean* (0.83, 1.45) P< Substantial healing, % patients (RGI-C +2.

Hypophosphatemic rickets: new treatments

burosumab (Crysvita )

The First Multi-Dose Trial of a Human Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) in Adults with X-Linked Hypophosphatemia (XLH)

About X-Linked Hypophosphatemia (XLH)

X-linked hypophosphatemic rickets across the lifespan

Discover CRYSVITA and Redefine XLH TREATMENT

DIAGNOSING X-LINKED HYPOPHOSPHATEMIA (XLH) BIOCHEMICAL TESTING CONSIDERATIONS

Clinical/Regulatory Updates of Burosumab and The Current Pre-launch Activities in EU

Conventional Therapy in Adults With X-Linked Hypophosphatemia: Effects on Enthesopathy and Dental Disease

CLINICAL TRIAL. 1 Yale School of Medicine, New Haven, CT, USA. 2 Centre d Evaluation des Maladies Osseuses, H^opital Cochin, Paris, France

X-Linked Hypophosphatemia in Adults New Biology, New Therapies

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION. Burosumab Injection. Solution for Subcutaneous Injection 10 mg/ml 20 mg/ml 30 mg/ml

Summary of late stage clinical trials. As of Jun. 30, 2018

FGF23 (and Klotho): what s new? Brief introduction to FGF23. Introduction to FGF23. FGF23: phosphorylation pathways. FGF23: phosphorylation pathways

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

The hart and bone in concert

STRENSIQ (asfotase alfa)

Pharmacokinetics/Pharmacodynamics. Abstract. Keywords

Diagnosis and Management of X-linked Hypophosphatemia (XLH)

Tenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia

Emerging Concepts in Pediatric Bone Disease

Sachin Soni DNB Pediatrics

Tenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia

Agent(s) FDA Labeled Indications Dosage and Administration. Perinatal/Infantile-onset hypophosphatasia. Juvenile-onset hypophosphatasia

Approach to a child presenting with rickets

A case of hereditary hypophosphataemic rickets with hypercalciuria (HHRH)

Hypophosphatasia. Tom Blevins, MD Texas Diabetes and Endocrinology Austin, TX

Summary of late stage clinical trials. As of Jul. 22, 2016

بسم هللا الرحمن الرحيم. Rickets

Protocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.

Rickets Simple complement 1. What factor influences on vitamin D absorption at the level of small intestine? A. Normal absorption of lipids B.

Corporate Presentation

Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease

MoveDMD SM : A Phase 1/2 Clinical Trial with CAT-1004 in Boys with Duchenne Muscular Dystrophy

Pediatric metabolic bone diseases

PFIZER INC. Study Centre: One centre from Hungary enrolled subjects in this study

Somavaratan (VRS-317) Treatment for Pediatric Growth Hormone Deficiency (GHD): VISTA Study Results at 2.5 Years (NCT )

Summary of late-stage clinical trials. As of Dec. 31, 2017

Klotho: renal and extra-renal effects

Supplementary Online Content

PFIZER INC. PROTOCOL TITLE: Metabolic effects of growth hormone (Genotonorm ) in girls with Turner syndrome.

Magnesium Homeostasis

See Important Reminder at the end of this policy for important regulatory and legal information.

Review Article Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism

FGF23 in CKD and ESRD Regulator of phosphorus balance, or much more than that?

PRIMARY HYPERPARATHYROIDISM WITH RICKETS. KRITHIKA.P Dr.L.N.Padmasani Unit 1 Sri Ramachandra Medical College

Clinical Policy: Asfotase Alfa (Strensiq) Reference Number: CP.PHAR.328 Effective Date: Last Review Date: 11.17

SYNOPSIS. Publications No publications at the time of writing this report.

MO Ped Trial FAQs. Page 1

OSTEOMALACIA UPDATE. Nothing to Disclose. Daniel D Bikle, MD, PhD Professor of Medicine University of California and VA Medical Center San Francisco

Summary of late stage clinical trials. As of Jun. 30, 2017

Nephrotoxic Effect of Vitamin D Therapy in

ResearchPoint Global, Inc., Austin, TX; 8 Versartis, Inc, Menlo Park, CA

Hypophosphatemic Rickets with Hypercalciuria

Efficacy, Safety and Tolerability of 150 mg Q2W Dose of the PCSK9 mab REGN727/SAR236553: Data from Three Phase 2 Studies

2.0 Synopsis. ABT-358 M Clinical Study Report R&D/06/099. (For National Authority Use Only) to Item of the Submission: Volume:

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Endocrine Regulation of Calcium and Phosphate Metabolism

Awaisheh. Mousa Al-Abbadi. Abdullah Alaraj. 1 Page

OPINION. Endocrine Journal 2015, 62 (8),

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

38 year old Male with Ankylosing Spondylitis. Olesya Krivospitskaya, MD April,

Disclosure. This study was sponsored by Pfizer, Inc. All authors are employees of Pfizer, Inc. with ownership of stock in Pfizer, Inc.

Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital

Inpatient Pediatric Endocrinology. Tala Dajani MD MPH Pediatric Endocrinology of Phoenix

Secondary Hyperparathyroidism: Where are we now?

Shon E. Meek, M.D., Ph.D. Assistant Professor of Medicine

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The Skeletal Response to Aging: There s No Bones About It!

Disclosure 7/2/2018. Consultant : Ultragenyx, Alexion, Ferrings. Research grant support: Ultragenyx, Shire, Amgen. Clinical Trial : Ultragynyx, Amgen

University of Zurich. What goes in must come out - the small intestine modulates renal phosphate excretion. Zurich Open Repository and Archive

PRIMARY PHASE 2 ANALYSES FROM CARDINAL: A PHASE 2/3 STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME

Summary of results. Name of the sponsor. Name of the finished product Name of active ingredient Title of the study

Dr Ranjith Kumar Dr S.Balasubramanian Unit KKCTH

Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age

Unexpected Widespread Hypophosphatemia and Bone Disease Associated with Elemental Formula Use in Infants and Children

The phosphatonin pathway: New insights in phosphate homeostasis.

PROs for Drug Development. Melanie Blank, MD

ADVERSE REACTIONS The most common (>10%) adverse reactions are hypercalcemia, nausea, and diarrhea. (6.

SERUM PHOSPHORUS TESTING

A Phase 1/2 Trial of Lumasiran (ALN-GO1), an Investigational RNAi Therapeutic for Primary Hyperoxaluria Type 1

Hypercalcemia. Hypercalcemia: When to Worry, When to Treat! Mineral Metabolism : A Short Course

Parsabiv (etelcalcetide) NEW PRODUCT SLIDESHOW

Research Article Effects of 1,25-Dihydroxycholecalciferol on Recovery and Resolution of Late Transient Neonatal Hypocalcemia

HEMLIBRA (emicizumab-kxwh) IN HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS

Management of Pediatric Fibrous Dysplasia/McCune-Albright Syndrome

Mipomersen (ISIS ) Page 2 of 1979 Clinical Study Report ISIS CS3

Skeletal Manifestations

National University Faculty of Medicine RICKETS. Dr. Gehan M. Osman MBBS, MD Pediatrics Jaffar Ibn Auf Specialized Hospital

Tenapanor, a minimally absorbed NHE3 inhibitor, reduces dietary phosphorus absorption in healthy volunteers

MS1 Physiology Review of Na+, K+, H + /HCO 3. /Acid-base, Ca+² and PO 4 physiology

Therapeutic golas in the treatment of CKD-MBD

What is the right calcium balance?

Transcription:

A Randomized, Open-label Phase 2 Study of, a Fully Human Anti-FGF23 Monoclonal Antibody, in 52 Children with X-linked Hypophosphatemia (XLH): 40-Week Results Thomas Carpenter Yale University School of Medicine New Haven, Connecticut, USA E. Imel, A. Boot, W. Högler, A. Linglart, R. Padidela, W. van t Hoff, M. Whyte, M. Mao, A. Skrinar, E. Kakkis, J. San Martin, A. Portale

Disclosures Dr. Carpenter: grant support and travel fees from Ultragenyx Pharmaceuticals Inc. (Ultragenyx) Drs. Imel, Boot, Linglart, Högler, van t Hoff, and Portale: travel and/or consulting fees from Ultragenyx. Dr. Padidela has received consulting fees from Ultragenyx and Alexion Pharmaceuticals Inc. Drs. Mao, Skrinar, Kakkis, and San Martin: employees of Ultragenyx Dr. Whyte: research grant support, honoraria, and travel from Ultragenyx and Alexion Pharmaceuticals Inc. This study was sponsored and funded by Ultragenyx in partnership with Kyowa Hakko Kirin Co., Ltd. Ting Chang, PhD (Ultragenyx) and Rebecca Lew, PhD CMPP (ProScribe) provided medical writing support

Children with XLH May Have Rickets, Skeletal Deformity, and Impaired Growth Rickets/Osteomalacia Bowing of the Leg Impairment of Linear Growth 190 170 150 Females 95% 75% 50% 25% 5% 190 170 150 Males 95% 75% 50% 25% 5% Height (cm) 130 110 Height (cm) 130 110 90 90 70 2 4 6 8 10 12 14 16 18 20 70 2 4 6 8 10 12 14 16 18 20 Age (years) Age (years)

Excess FGF23 in the Pathophysiology of XLH PHEX mutation Bone produces FGF23 1- hydroxylase 1,25(OH) 2 D Defective mineralization and delayed ossification NaPi-2a NaPi-2c Urine NaPi2a/NaPi2c Cotransporters Renal Tubule Cell FGFR FGF23 Capillary Downregulated Phosphate Cotransport -KLOTHO Phosphate Absorption Phosphate Excretion Serum Phosphate Phosphate Razzaque MS. Nat Rev Endocrinol 2009;5:611-9. Martin A, et al. Physiol Rev 2012;92:131-55.

, a Monoclonal Antibody, Binds and Inhibits FGF23 PHEX mutation Bone produces FGF23 Designed to Inhibit Serum FGF23 Proposed Mechanism of Action of, an Investigational Product 1- hydroxylase 1,25(OH) 2 D Improved mineralization and bone disease expected NaPi-2a NaPi-2c Urine NaPi2a/NaPi2c Cotransporters Renal Tubule Cell FGFR -KLOTHO Capillary FGF23 Phosphate Transport Phosphate Absorption Phosphate Excretion Serum Phosphate Phosphate

Pediatric Phase 2 Study Design (UX023-CL201) Study Population Children with XLH Ages 5-12 yrs N = 52 Tanner 2 Weeks Study Design Titration Period 16 Weeks Titration Period 16 Weeks Biweekly (Q2W) Dose Group Treatment Period 48 Weeks Monthly (Q4W) Dose Group Treatment Period 48 Weeks 0 16 40 64 Extension Study Primary analysis: Week 40 (N=52) Extended analysis: Week 64 (N=36) Pre-specified subgroups based on baseline total rickets severity score (RSS) Week 40: 34 patients with RSS 1.5; 18 patients with RSS < 1.5 Week 64: 18 patients with RSS 1.5; 18 patients with RSS < 1.5 Key Endpoints Pharmacodynamics: serum P, TRP, TmP/GFR, 1,25(OH) 2 D Rickets -- graded by two scoring systems (RGI-C and RSS) Growth velocity Walking ability: 6 minute walk test Patient-reported Outcome: POSNA- PODCI Safety

Two Rickets Scoring Systems Thacher Rickets Severity Score (RSS) Total 0-10: wrist (0-4) plus knee (0-6) Read centrally by an expert blinded to dose and patient Radiographic Global Impression of Change (RGI-C) 7-point scale describing changes at wrist, knee, and leg during treatment X-rays read by 3 independent experts blinded to dose -3-2 -1 0 +1 +2 +3 Severe Worsening Moderate Worsening Minimal Worsening No Change Minimal Healing Substantial Healing Complete or Near Complete Healing Score 1.0 Score 2.0 Knee X ray

Baseline Characteristics of the Two Subsets Q2W (N = 26) Q4W (N = 26) Overall (N = 52) Q2W (N = 18) Q4W (N = 18) Overall (N = 36) Age, yrs 8.7 (1.7) 8.3 (2.0) 8.5 (1.9) 8.3 (1.6) 8.1 (2.1) 8.2 (1.8) Male 12 (46%) 12 (46%) 24 (46%) 9 (50%) 9 (50%) 18 (50%) White 23 (89%) 23 (89%) 46 (89%) 16 (89%) 16 (89%) 32 (89%) Weight, kg 31.9 (7.9) 29.1 (10.7) 30.5 (9.4) 30.1 (7.6) 28.1 (11.2) 29.1 (9.5) Height Z score -1.7 (1.0) -2.1 (1.0) -1.9 (1.0) -1.6 (1.0) -2.2 (1.0) -1.9 (1.0) RSS total score Range Received prior oral P / active vitamin D Duration of prior oral P / active vitamin D, yrs Week 40 Subset 1.9 (1.2) (0, 4.5) 1.7 (1.0) (0, 3.0) 1.8 (1.1) (0, 4.5) 1.5 (1.1) (0, 3.5) Week 64 Subset 1.3 (1.0) (0, 3.0) 1.4 (1.0) (0, 3.5) 25 (96%) 24 (92%) 49 (94%) 17 (94%) 17 (94%) 34 (94%) 6.7 (2.5) 6.7 (2.7) 6.7 (2.6) 6.9 (1.9) 6.7 (2.8) 6.8 (2.4) Values as mean (SD), median (min, max), or n (%) as indicated. Q2W, biweekly; Q4W, monthly; P, phosphate; RSS, Thacher Rickets Severity Score; SD, standard deviation

Improvement in Serum Phosphorus, TmP/GFR, and 1,25(OH) 2 D Serum Phosphorus (mg/dl) TmP/GFR (mg/dl) 4.2 3.6 3.0 2.4 1.8 4.2 3.6 3.0 2.4 1.8 Q2W Q4W Mean doses (SD) at Week 40: Q2W: 1.0 (0.4) mg/kg 34.7 (20.5) mg/dose Q4W: 1.5 (0.4) mg/kg 45.5 (19.3) mg/dose All treatment values were significant compared with baseline No hyperphosphatemia in any patient 130 1,25(OH) 2 D (pg/ml) 90 50 10 0 2 14 16 28 38 40 Week 54 56 62 64

Rickets Severity Score (RSS) Week 40 (N=52) RSS Total Score 3.0 2.5 2.0 1.5 1.0 0.5 All Patients Baseline RSS Total Score 1.5 61% 37% 50% 3.0 2.5 71% 48% 61% 2.0 1.5 1.0 0.5 Q2W (N=26) Q4W (N=26) All (N=52) Q2W (N=17) Q4W (N=17) All (N=34) Week 64 (N=36) RSS Total Score 3.0 2.5 2.0 1.5 1.0 0.5 51% 25% Q2W (N=18) Q4W (N=18) All (N=36) 38% Mean values ± SE; p 08 for all groups based on the Analysis of Covariance (ANOVA) model for the Week 40 subset and the Generalized Estimation Equation (GEE) for the Week 64 subset; 3.0 2.5 2.0 1.5 1.0 0.5 Baseline Week 40 Week 64 57% 44% Q2W (N=9) Q4W (N=9) All (N=18) 51%

Radiographic Global Impression of Change (RGI-C) Week 40 (N=52) Mean RGI-C Score + 3.0 + 2.5 + 2.0 + 1.5 + 1.0 + 0.5 All Patients (N=52) 1.72 1.41 1.56 Q2W (N=26) Q4W (N=26) All (N=52) Baseline RSS Total Score 1.5 (N=34) + 3.0 + 2.5 + 2.0 + 1.5 + 1.0 + 0.5 2.04 1.78 1.91 Q2W (N=17) Q4W (N=17) All (N=34) Week 64 (N=36) Mean RGI-C Score + 3.0 + 2.5 + 2.0 + 1.5 + 1.0 + 0.5 1.56 1.35 1.20 1.35 1.38 1.35 Q2W (N=18) Q4W (N=18) All (N=36) Week 40 Week 64 p < 001 for all groups based on the Analysis of Covariance (ANOVA) model for the Week 40 subset and the Generalized Estimation Equation (GEE) for the Week 64 subset; Error bars = SE; RGI-C Scores: +1.0 = minimal healing; +2.0 = substantial healing; +3.0 = complete or near complete healing + 3.0 + 2.5 + 2.0 + 1.5 + 1.0 + 0.5 2.00 1.96 1.70 1.85 1.85 1.91 Q2W (N=9) Q4W (N=9) All (N=18)

Radiographic Appearance of Rickets at Baseline and Follow-up Knee radiographs in ~11-year-old girl with XLH during therapy demonstrate improved rachitic findings at the growth plate Baseline 40 weeks 64 weeks RSS Total Score 3.5 1.0 RGI-C Global Score +2.0 +2.3

Standing Height Z-score Change From Baseline Week 40 (N=52) Week 64 (N=36) LS Mean Change from Baseline LS Mean Change from Baseline 0.3 0.2 0.1 0-0.1 0.4 0.3 0.2 0.1 0-0.1 Q2W (N=26) Q4W (N=26) All Patients 0 16 24 40 Weeks Q2W (N=18) Q4W (N=18) 0 16 24 40 Weeks p < 001 Baseline RSS Total Score 1.5 0.3 0.2 0.1 0-0.1 0.4 0.3 0.2 0.1 0 Q2W (N=17) Q4W (N=17) 0 16 24 40 Weeks Q2W (N=9) Q4W (N=9) -0.1 64 0 16 24 40 Error bars = SE Weeks p < 001 p < 001 p < 06 p < 3 p = 1 64

Growth Velocity Week 40 (N=52) Growth Velocity (cm/year) 8.0 6.0 4.0 2.0 All Patients 6.41 * 5.45 5.24 5.63 6.03 ± 5.35 8.0 6.0 4.0 2.0 Baseline RSS Total Score 1.5 6.74 * 5.77 6.28* 5.05 5.07 5.06 Q2W (N=26) Q4W (N=26) All (N=52) Q2W (N=17) Q4W (N=17) All (N=34) Week 64 (N=36) Growth Velocity (cm/year) 8.0 6.0 4.0 2.0 5.68 6.04 5.50 5.70 5.59 5.87 ± 5.88 5.14 5.47 5.87 5.87± 5.29 Q2W (N=18) Q4W (N=18) All (N=36) Q2W (N=9) Q4W (N=9) All (N=18) Baseline Week 40 Week 64 * p 1; ± p 5 compared with baseline based on one sample t test; Error bars = SE 8.0 6.0 4.0 2.0

6MWT and Functional Ability at Week 40 LS Mean Change from Baseline (± SE) in Meters 100 90 80 70 60 50 40 30 20 10 0 Patients with Impaired Walking Ability at Baseline (< 80% Predicted; N=24) Q2W (N=14) +84 m p < 001 0 16 24 40 Weeks Q4W (N=10) Mean (± SE) Normative Score 60 50 40 30 20 10 0 Patients with Global Functional Impairment at Baseline (POSNA-PODCI Score <40; N=28) Upper Extremity Transfers/BasicSports/Physical Mobility Functioning Baseline Week 40 Pain/Comfort Global Functioning All treatment values were significant compared with baseline using the generalized estimation equation (GEE) model with the exception of the Q4W group for the 6MWT. POSNA-PODCI Pediatric Orthopedic Society of North America-Pediatric Outcome Data Collection Instrument

Summary of Safety Measures Patient Incidence, n (%) Q2W (N=26) Q4W (N=26) Overall (N = 52) Any adverse events (AEs) 26 (100%) 26 (100%) 52 (100%) Drug-related AEs* 17 (65%) 18 (69%) 35 (67%) Injection site reaction 7 (27%) 10 (39%) 17 (33%) erythema 8 (31%) 5 (19%) 13 (25%) swelling 4 (15%) 1 (4%) 5 (10%) rash 2 (8%) 2 (8%) 4 (8%) Pain in extremity 3 (12%) 2 (8%) 5 (10%) Vitamin D Deficiency 1 (4%) 4 (15%) 5 (10%) Arthralgia 2 (8%) 1 (4%) 3 (6%) Myalgia 1 (4%) 2 (8%) 3 (6%) Serious AEs 0 1 (4%) 1 (2%) AEs leading to discontinuation 0 0 0 AEs leading to death 0 0 0 * Assessed by investigator as possibly/probably related to investigational product; most common ( 3 patients) drug-related AEs are listed

Summary and Conclusions In children with XLH treated with for up to 64 weeks: TmP/GFR, serum P, and serum 1,25(OH) 2 D increased Rickets improved significantly despite previous conventional treatment for a mean of ~7 years Improvements in rickets scores were greater in patients with more severe baseline rickets (RSS 1.5) receiving Q2W dosing 94% at Week 40 and 89% at Week 64 had substantial healing of rickets improved growth, walking ability, and functional ability. was well tolerated No clinically meaningful changes were observed in serum PTH, serum or urine calcium, or renal ultrasounds. Hyperphosphatemia was not observed Inhibition of FGF23 improves clinical outcomes in children with XLH